wards luminal differentiation. Conclusions: The switch towards luminal phenotype suggests some kind of endocrine effect of NAC. Our findings raise renewed interest in combinatorial cytotoxic chemotherapy with concomitant or rather sequential endocrine therapy, either alone or with targeted agents.
Introduction
Neoadjuvant chemotherapy (NAC) was originally introduced to reduce tumor size and enable surgery of locally advanced breast cancer (BC) [1] . Subsequent meta-analyses showed no differences in outcome between pre-and post-operative chemotherapy [2] . More recently, NAC has been considered as a unique opportunity to understand BC biology, thanks to the possibility of analyzing paired tumor samples before and after treatment [3] . The agents developed in this setting are similar to those validated in the adjuvant context, anthracyclines and taxanes being the most effective compounds [4] . Previous studies investigated the relation between Ki-67 drop and response to NAC. More recently, scientific interest was raised by the effects of NAC on hormone receptor (HR) and HER2 expression. Nevertheless, most previous works focused on small populations and various cytotoxic regimens. The objective of this study was to address BC phenotype changes in a homogeneous population of patients with localized or metastatic disease, mostly treated with anthracycline and taxane-based NAC within the same institution.
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Summary
Background: Breast cancer (BC) phenotype after neoadjuvant chemotherapy (NAC) has not been extensively described and few data exist on whether expression of the primary tumor hormone receptors, HER2 and Ki-67 changes as a result of chemotherapy. Materials and Methods: We analyzed specimens from all BC patients treated with anthracycline/taxane-based NAC at our Institution between January 2010 and March 2015 (n = 325). The expression of estrogen receptor (ER), progesterone receptor (PR), HER2 and Ki-67 was determined in pre-and post-NAC specimens. McNemar's test was used to compare paired proportions. Results: Among patients with residual disease after NAC, basal phenotype was luminal A, luminal B, HER2 positive and triple negative in 44, 111, 74 and 27 cases, respectively. PR-positive tumors decreased from 68.0% in the initial biopsy sample to 61.7% in the surgical specimen (p = 0.024). A Ki-67 of < 20% increased from 23.6% to 45% (p < 0.001). ER expression changed from positive to negative in 5% and from negative to positive in 16.7% of cases. Overall, 30% of cases underwent subtype changes, 79% of them to- 
Materials and Methods
We retrospectively collected information from the institutional database on all consecutive BC patients treated with NAC who underwent surgery at the Istituto Nazionale dei Tumori, Milan, Italy, between 1 January 2010 and 31 March 2015. For the current analysis we excluded all cases treated with chemotherapy in our Institution but undergoing surgery in other Institutions, as well as those without paired basal and surgical histological specimens and/or those treated with experimental therapy within a clinical trial. Data about patients' age, NAC regimen and duration, type and timing of surgery, clinical and pathological BC stage, and disease phenotype before and after NAC were extracted. All cases obtaining pathological complete response (pCR) were excluded from analysis. In absence of contraindications, all patients received anthracycline and taxane-based NAC. All HER2-positive cases were treated with trastuzumab, according to international guidelines. HR and HER2 status, Ki-67 index and disease stage were examined by Institutional pathologists. Diagnostic cut-offs for HR and HER2 positivity were defined according to American Society of Clinical Oncology-College of American Pathologists (ASCO-CAP) guidelines [5, 6] . Tumor subtype classification followed the St. Gallen/Vienna 2015 criteria [7] . All surgical specimens were completely sampled to detect residual disease. pCR was defined as the absence of invasive disease in both breast and lymph nodes. The primary objective of the study was to estimate percentage of changes in HR and HER2 status after NAC. Secondary objective was to compare percentage of cases with a specific tumor receptor status between pre-and post-NAC setting. 2-sided 95% exact confidence intervals (CIs) were calculated to estimate percentage of patients changing BC subtype. The 2-sided exact McNemar's test was used to assess equality of basal and surgical paired percentages. Patients' and tumor characteristics, NAC regimens and disease response were summarized using descriptive statistics (median and range for continuous variables, absolute and percentage frequencies for categorical ones). Median follow-up was estimated using the reverse Kaplan-Meier method. Given the descriptive nature of the study, a quantitative hypothesis testing was applied instead that a formal one (e.g. no thresholds for statistical significance were defined). Statistical analysis was performed using SAS software, version 9.2 (SAS Institute, Cary, NC, USA).
Results
We identified 325 case with a median age of 51 years (range 23-85 years). Details about patients' and tumor characteristics are summarized in table 1 and table 2 . 31 patients achieved pCR and were therefore excluded from analysis. Among the 294 patients with residual disease at surgery, paired tissue samples for determination estrogen receptor (ER) status at diagnostic biopsy and surgery were available in 274 cases (93.2%). 11 of 220 (5.0%, CI 2.5-8.8%) patients showed a change from ER-positive to ER-negative disease. 9 of 54 (16.7%, CI 7.9-29.3) patients converted from ERnegative to ER-positive disease. 34 of 183 (18.6%, CI 13.2-25.0%) cases with progesterone receptor (PR)-positive primary tumor had PR-negative residual disease at surgery. 17 of 86 (19.8%, CI 12.0-29.8%) cases with PR-negative disease showed PR-positivity at surgery. Among the 239 patients tested for HER2 in initial biopsy and surgical specimen, HER2 changed from positive to negative in 9 of 49 (18.4%, CI 8.8-32.0%) patients and from negative to positive in 7 of 190 (3.7%, CI 1.5-7.4%). Among the 229 cases with paired values of Ki-67, its expression decreased from 20% to < 20% in 63 of 175 (36.0%, CI 28.9-43.6%) patients and increased from < 20% to 20% 
Discussion
Change in HR and HER2 status after NAC is a well-known phenomenon in BC, occurring in 10-30% of cases [8, 9] . Although the older results might be affected by pre-analytical and analytical pitfalls [10, 11] , a real biological heterogeneity may be implied. It was hypothesized that paired samples from a single lesion may differ, even in absence of therapeutic interventions, as a consequence of malignant subpopulations coexistence. Some studies supported this theory, identifying no differences in phenotype change rates between paired samples from treatment-naïve and chemo-treated patients [12, 13] . An alternative hypothesis supports a drug-induced selection pressure towards malignant cells. Cytotoxic, endocrine and biological agents may specifically target and kill sensitive BC subpopulations, leaving behind the resistant ones. This hypothesis was sustained by some studies, showing higher frequency of BC phenotype change in NAC-treated patients than in naïve controls [14, 15] . The present work shows that most cases undergoing phenotype changes presented with advanced stage (pT3-4, pN+, cM+). This observation is in favor of the hypothesis that treatment might possibly affect part of a rather heterogeneous disease, leading to the emergence of an unresponsive residue. On the other hand, a considerable amount of data suggests that Ki-67 drop after NAC may be an independent positive prognostic factor in patients not achieving pCR [16, 17] . In the present study, we observed a significant decrease in PR and Ki-67 expression after NAC. This finding seems to support a prognostic, rather than an incidental role of BC phenotype change during NAC. Previous works postulated that cytotoxic agents may play an endocrine role, suppressing ovarian and adrenal function with consequent alteration of BC biological profile [18] . Indeed, it was shown that pre-menopausal women with HR-positive tumors attaining amenorrhea after NAC had better outcome than menstruating women [19] . Post-menopausal patients may also achieve benefit, due to adrenal endocrine suppression induced by cytotoxic agents [20] . If confirmed, these hypotheses may entail important clinical implications, as PR decrease may be viewed as a marker of reduced endocrine stimulation in BC. Another finding of this study concerns the tendency towards luminal differentiation observed after NAC. Even though our data do not allow prognostic or pathogenetic conclusions to be drawn, this previously unreported finding is in line with the hypothesis of an endocrine effect of chemotherapy. This observation potentially raises new interest in the development of sequential cytotoxic and hormonal NAC approaches, or combinations with innovative drugs such as cyclin kinase inhibitors, to target biological modifications of tumor phenotype induced by standard NAC. A plethora of gene expression profiles have been generated during the last decades to discover, develop and validate prognostic and predictive gene signatures. Some of these signatures are commercially available to define the residual risk in ER-positive and HER2-negative tumors after receiving adjuvant endocrine treatment (Mammaprint, Oncotype DX, Breast Cancer Index, PAM50, EndoPredict) [21] . Unfortunately, none of these signatures were aimed at specifically defining the residual risk after standard NAC. Our findings obtained using the St. Gallen criteria for BC classification suggest that gene expression profiling of residual disease could help to further characterize the modifications induced by anthracycline/taxane NAC, with the final goal of defining patients at high recurrence risk despite standard treatment, who could be ideal candidates for trials with investigational drugs in early breast cancer. A significant value of our study consists in the focus on a homogeneous population, treated over a limited period of time. Furthermore, the cytotoxic and biological agents administered were in agreement with recent guidelines on NAC. However, some limitations of this work have to be underlined. First of all, it represents a retrospective case series based on a limited number of patients. Secondly, immature follow-up does not allow outcome conclusions to be drawn. Finally, this study was conceived as an explorative analysis without pre-defined postulates, with a speculative and hypothesis-generating aim.
In conclusion, the reported data suggest that NAC may induce distinct phenotypical changes in BC. We believe this observation deserves further evaluation as it may entail crucial implications in the development of new neoadjuvant therapeutic strategies.
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